Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 1561 results for do not do recommendations

  1. Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    Recommendation ID IPG737/01 Question Evidence on the safety and efficacy of prostatic urethral temporary implant insertion for lower...

    Research recommendation
    Published
    30 September 2022

  2. Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory non-specific chronic low back pain is limited in quantity and quality. Therefore, this procedure should only be used with special arrangements for clinical governance, consent, and audit or research. Find out what special arrangements mean on the NICE interventional procedures guidance page.

    Recommendation ID IPG739/01 Question Evidence on the efficacy and safety of neurostimulation of lumbar muscles for refractory...

    Research recommendation
    Published
    30 September 2022

  3. Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse:- What is the effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to drug misuse in the UK?

    Recommendation ID NG64/3 Question Effectiveness and cost effectiveness of drug misuse prevention interventions for groups vulnerable to

    Research recommendation
    Published
    4 May 2017

  4. Recognising dying:- What can multiprofessional teams do to reduce the impact of uncertainty of recognising when a person is entering the last days of life on clinical care, shared decision-making and communication with the dying person and those important to them?

    Recommendation ID NG31/1 Question Recognising dying:- What can multiprofessional teams do to reduce the impact of...

    Research recommendation
    Published
    27 January 2016

  5. What is the effectiveness, cost effectiveness and acceptability of the whole family approach to carers' assessments?

    Recommendation ID NG150/1 Question What is the effectiveness, cost effectiveness and acceptability of the whole family approach to...

    Research recommendation
    Published
    10 February 2020

  6. Apremilast for treating moderate to severe plaque psoriasis (TA419)

    Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.

    Technology appraisal guidance
    Published
    23 November 2016
    View recommendations

    Sections for TA419

  7. Our research work

    Our science policy and research programme team produces high-quality, impactful research.

  8. Recommendation 1 Research studies and trials. Who should take action? Research councils, commissioners and funders.

    Recommendation ID PH47/1 Question Recommendation 1 Research studies and trials. Who should take action? Research councils,...

    Research recommendation
    Published
    9 June 2015

  9. Recommendation 4 Weight management programmes. Who should take action? Research councils, commissioners and funders. Researchers and investigators.

    Recommendation ID PH47/4 Question Recommendation 4 Weight management programmes. Who should take action? Research councils,...

    Research recommendation
    Published
    9 June 2015

  10. Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over (TA967)

    Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.

    Technology appraisal guidance
    Published
    1 May 2024
    View recommendations

    Sections for TA967

  11. Esketamine nasal spray for treatment-resistant depression (TA854)

    Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.

    Technology appraisal guidance
    Published
    14 December 2022
    View recommendations

    Sections for TA854

  12. Midcarpal hemiarthroplasty for wrist arthritis (HTG529)

    Evidence-based recommendations on midcarpal hemiarthroplasty for wrist arthritis in adults. This involves using a metal implant to create an artificial wrist joint, to relieve pain and maintain movement.

    HealthTech guidance
    Published
    16 October 2019
    View recommendations

    Sections for HTG529

  13. Molnupiravir for treating COVID-19 (TA1056)

    Evidence-based recommendations on molnupiravir (Lagevrio) for treating mild to moderate COVID-19 in adults who have a positive SARS-CoV-2 test.

    Technology appraisal guidance
    Published
    16 April 2025

    Sections for TA1056

  14. Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)

    Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.

    Highly specialised technologies guidance
    Published
    19 April 2023
    View recommendations

    Sections for HST26

  15. Transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation (HTG752)

    Evidence-based recommendations on transcatheter aortic valve implantation (TAVI) for native aortic valve regurgitation. This involves implanting a replacement valve inside the faulty native valve.

    HealthTech guidance
    Published
    24 June 2025
    View recommendations

    Sections for HTG752